Conflict of interest
Johnson & Johnson Health Care Systems, EPS
Ken Kato has received research grants from AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Merck & Co., Oncolys BioPharma Inc., Ono Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Taiho Pharmaceuticals Co., Ltd.; received honoraria and consulting fees from Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Merck & Co., Ono Pharmaceutical Co., Ltd., and Taiho Pharmaceuticals Co., Ltd.; and received consulting fees from AstraZeneca, Bayer, and BeiGene. Yuichiro Doki has received research grants and speaker engagement fees from Abbott, Ajinomoto Pharmaceuticals, Astellas Pharma Inc., AstraZeneca, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd.; Eisai Co., Ltd., Eli Lilly & Co., Johnson & Johnson Health Care Systems Inc., Kaken Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Yakult Honsha Co. Ltd.; received research grants from CSL Behring, Nestle HealthCare Nutrition Inc., Nippon Kayaku, Novartis Pharma, and Pfizer; and received speaker engagements fees from Asahi Kasei Pharma Corporation, Intuitive Surgical, Medtronic, Merck & Co., Olympus Corporation, Otsuka Pharmaceutical Co., Ltd., Sanofi, and Teijin Pharma Ltd. Takashi Ogata has received honoraria for lectures from Bristol Myers Squibb and Ono Pharmaceutical Co., Ltd. Satoru Motoyama has received institutional research grants from Kaken Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., Shionogi & Co., Ltd., Taiho Pharmaceuticals Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; received advisory board fees and honoraria from Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Merck & Co., and Ono Pharmaceutical Co., Ltd.; and honoraria from Kaken Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Factory Inc. Hisato Kawakami has received institutional research grants from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Kobayashi Pharmaceutical. Co., Ltd., and Taiho Pharmaceuticals Co., Ltd.; consulting fees from Daiichi-Sankyo Co., Ltd.; and honoraria from Bayer, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and Yakult Honsha Co. Ltd. Takashi Kojima has received institutional research grants from Amgen Inc., BeiGene, Chugai Pharmaceutical Co., Ltd., EPS Corporation, Merck & Co., Parexel International, Shionogi & Co., Ltd., and Taiho Pharmaceuticals Co., Ltd.; received honoraria from Bristol Myers Squibb, Covidien Japan, Inc., Merck & Co., Oncolys BioPharma Inc, Ono Pharmaceutical Co., Ltd., and Taiho Pharmaceuticals Co., Ltd.; and participated on data safety monitoring or advisory board of Astellas Pharma Inc., Bristol Myers Squibb, Merck & Co., and Oncolys BioPharma Inc. Morihito Okada has received institutional research grants and honoraria from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Covidien Japan, Inc., Daiichi-Sankyo Co., Ltd., Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., Merck & Co., and Pfizer Inc.; and research grants from Clinipace, Eli Lilly & Co., Kissei Pharmaceutical Co., Ltd., Kyouwa Hakkou Kirin Co., Ltd., Mitsubishi Tanabe Pharma, Nihon Medi-Physics Co., Ltd., Ono Pharmaceutical Co., Ltd., Parexel International, and Taiho Pharmaceuticals Co., Ltd. Ryu Ishihara received honoraria from AstraZeneca, Daiichi-Sankyo Co., Ltd., EA Pharma Co., Ltd., Fujifilm, Olympus Corporation, and Ono Pharmaceutical Co., Ltd. Carlos Amaya Chanaga is an employee of Bristol Myers Squibb and has stocks of AbbVie and Bristol Myers Squibb. Tien Chen is an employee of Bristol Myers Squibb, and has stocks and a patent issued by Bristol Myers Squibb. Yasuhiro Matsumura is an employee and holds stocks of Ono Pharmaceutical Company Ltd. Yuko Kitagawa has received institutional research grants from Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., EA Pharma Co., Ltd., Eisai Co., Ltd., Kaken Pharmaceutical Co., Ltd., Kyouwa Hakkou Kirin Co., Ltd., Medicon Inc., Merck & Co., Nihon Pharmaceuticals Co. Ltd., Nippon Covidien Inc., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., Taiho Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Tsumura & Co., and Yakult Honsha Co. Ltd.; and received honoraria from Asahi Kasei Pharma Corporation, Aska Pharmaceutical Co., Ltd., AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Ethicon Inc., Kaken Pharmaceutical Co., Ltd., Merck & Co., Nippon Covidien Inc., Olympus Corporation, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Smith & Nephew KK, and Taiho Pharmaceuticals Co., Ltd. Masaki Ueno, Yutaro Kubota, and Yasuhiro Shirakawa have nothing to disclose.